Percutaneous Ethibloc injection in the treatment of primary aneurysmal bone cysts

J Pediatr Orthop B. 2005 Sep;14(5):367-70. doi: 10.1097/01202412-200509000-00010.

Abstract

The effects of percutaneous Ethibloc (Ethicon/Johnson & Johnson, St-Stevens-Woluwe, Belgium) injection into primary aneurysmal bone cysts were analysed. Two patients with a venous drainage after injection of a medium contrast were excluded. Twelve patients underwent at least one percutaneous injection of Ethibloc. The average follow-up period was 5.1 years. At final follow-up, six patients had complete healing of the cyst, three had partial healing and three, who had no response, were treated by curettage and bone grafting. Complete healing was observed for all the aggressive lesions. No major complications were noted. Ethibloc injection may be performed as a primary treatment of aneurysmal bone cysts if the technique is followed with precision.

Publication types

  • Clinical Trial

MeSH terms

  • Acetaminophen / therapeutic use
  • Adolescent
  • Analgesics, Non-Narcotic / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Bone Cysts, Aneurysmal / drug therapy*
  • Child
  • Child, Preschool
  • Diatrizoate / therapeutic use*
  • Drug Combinations
  • Fatty Acids / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intralesional
  • Male
  • Propylene Glycols / therapeutic use*
  • Sclerosing Solutions / therapeutic use*
  • Treatment Outcome
  • Zein / therapeutic use*

Substances

  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Drug Combinations
  • Fatty Acids
  • Propylene Glycols
  • Sclerosing Solutions
  • Diatrizoate
  • Acetaminophen
  • Zein
  • alcoholic prolamine solution